Research graph
References from Development of Pharmacotherapies for the Treatment of Sarcopenia. Local targets link to admitted publications; unresolved targets remain external evidence.
Ageing populations: the 1. Cruz-Jentoft AJ, Landi F, Schneider SM, et al. Prevalence of and interventions for sarcopenia in ageing adults: a systematic review. Report of the International Sarcopenia Initiative (EWGSOP and IWGS)
10.1093/ageing/afu115 · 2014 · External reference
The healthcare costs of sarcopenia in the United States
10.1111/j.1532-5415.2004.52014.x · 2004 · External reference
Sarcopenia
10.1016/j.berh.2017.11.007 · 2017 · External reference
Aging of skeletal muscle: a 12-yr longitudinal study
10.1152/jappl.2000.88.4.1321 · 2000 · External reference
Innervation and neuromuscular control in ageing skeletal muscle
10.1113/jp270561 · 2016 · External reference
Sarcopenia: burden and challenges for public health
10.1186/2049-3258-72-45 · 2014 · External reference
Fighting the inevitability of ageing
10.1038/d41586-018-02479-z · 2018 · External reference
Unresolved reference
2017 · External reference
Unresolved reference
2018 · External reference
Exercise and physical activity for older adults
10.1249/mss.0b013e3181a0c95c · 2009 · External reference
Highintensity strength training in nonagenarians. Effects on skeletal muscle
10.1001/jama.1990.03440220053029 · 1990 · External reference
Strength conditioning in older men: skeletal muscle hypertrophy and improved function
10.1152/jappl.1988.64.3.1038 · 1988 · External reference
Effectiveness of exercise interventions on physical function in community-dwelling frail older people: an umbrella review of systematic reviews
10.11124/jbisrir-2017-003551 · 2018 · External reference
Effect of structured physical activity on prevention of major mobility disability in older adults: the LIFE study randomized clinical trial
10.1001/jama.2014.5616 · 2014 · External reference
Dose of physical activity, physical functioning and disability risk in mobility-limited older adults: Results from the LIFE study randomized trial
10.1371/journal.pone.0182155 · 2017 · External reference
Effects of resistance training, endurance training and whole-body vibration on lean body mass, muscle strength and physical performance in older people: a systematic review and network metaanalysis
10.1093/ageing/afy009 · 2018 · External reference
Progressive resistance strength training for improving physical function in older adults
2009 · External reference
Unresolved reference
2013 · External reference
Protein requirements and recommendations for older people: A review
10.3390/nu7085311 · 2015 · External reference
Nutritional intervention in sarcopenia: Report from the International Conference on Frailty and Sarcopenia Research Task Force
2018 · External reference
Physical inactivity among older adults across Europe based on the SHARE database
10.1093/ageing/afw165 · 2017 · External reference
Cross-sectional and longitudinal factors influencing physical activity of 65 to 75-year-olds: a pan European cohort study based on the survey of health, ageing and retirement in Europe (SHARE)
10.1186/s12877-018-0781-8 · 2018 · External reference
Unresolved reference
2017 · External reference
Adherence to physical exercise recommendations in people over 65—the SNAC-Kungsholmen study
10.1093/eurpub/cks150 · 2013 · External reference
Effects of exercise and aging on skeletal muscle
10.1101/cshperspect.a029785 · 2018 · External reference
Effects of protein supplementation combined with resistance exercise on body composition and physical function in older adults: a systematic review and meta-analysis
10.3945/ajcn.116.143594 · 2017 · External reference
Does nutrition play a role in the prevention and management of sarcopenia
10.1016/j.clnu.2017.08.016 · 2018 · External reference
Physical frailty and sarcopenia (PF&S): a point of view from the industry
10.1007/s40520-016-0710-7 · 2017 · External reference
Signaling pathways controlling skeletal muscle mass
10.3109/10409238.2013.857291 · 2014 · External reference
Myostatin/activin pathway antagonism: Molecular basis and therapeutic potential
10.1016/j.biocel.2013.05.019 · 2013 · External reference
Sarcopenia: origins and clinical relevance
10.1093/jn/127.5.990s · 1997 · External reference
Sarcopenia: European consensus on definition and diagnosis Report of the European Working Group on Sarcopenia in Older People
10.1093/ageing/afq034 · 2010 · External reference
Consensus definition of sarcopenia, cachexia and pre-cachexia: joint document elaborated by Special Interest Groups (SIG) “cachexia-anorexia in chronic wasting diseases” and “nutrition in geriatrics”
10.1016/j.clnu.2009.12.004 · 2010 · External reference
Sarcopenia: an undiagnosed condition in older adults. Current consensus definition: prevalence, etiology, and consequences. International working group on sarcopenia
10.1016/j.jamda.2011.01.003 · 2011 · External reference
Sarcopenia in Asia: Consensus report of the Asian working group for sarcopenia
2014 · External reference
The FNIH sarcopenia project: rationale, study description, conference recommendations, and final estimates
10.1093/gerona/glu010 · 2014 · External reference
Sarcopenia: revised European consensus on definition and diagnosis
10.1093/ageing/afy169 · 2019 · External reference
Sarcopenia is associated with incident disability, institutionalization, and mortality in community-dwelling older men: The Concord Health and Ageing in Men project
10.1016/j.jamda.2015.02.006 · 2015 · External reference
Prevalence of sarcopenia in community-dwelling Chilean elders according to an adapted version of the European Working Group on Sarcopenia in Older People (EWGSOP) criteria
2017 · External reference
The prevalence of sarcopenia in very old individuals according to the European consensus definition: insights from the BELFRAIL study
10.1093/ageing/aft128 · 2013 · External reference
Ethnic and geographic variations in muscle mass, muscle strength and physical performance measures
10.1016/j.eurger.2014.04.003 · 2014 · External reference
Prevalence of sarcopenia in communitydwelling Japanese older adults
10.1016/j.jamda.2013.08.015 · 2013 · External reference
The Gambian Bone and Muscle Ageing Study: Baseline data from a prospective observational African sub-Saharan study
10.3389/fendo.2017.00219 · 2017 · External reference
Sarcopenia trials in specific diseases: Report by the International Conference on Frailty and Sarcopenia Research Task Force
2016 · External reference
The assessment and impact of sarcopenia in lung cancer: a systematic literature review
2014 · External reference
Prevalence of sarcopenia and diagnostic ability assessment of widely available methods of muscle mass and performance estimation in cirrhotic patients
10.1016/j.clnesp.2018.01.053 · 2018 · External reference
Sarcopenia in COPD: prevalence, clinical correlates and response to pulmonary rehabilitation
10.1136/thoraxjnl-2014-206440 · 2015 · External reference
Sarcopenia in peripheral arterial disease: Prevalence and effect on functional status
10.1016/j.apmr.2017.10.017 · 2018 · External reference
Sarcopenia and physical function in middle-aged and older stroke survivors
10.1016/j.apmr.2016.07.015 · 2017 · External reference
Therapeutic considerations of sarcopenia in heart failure patients
10.1080/14779072.2018.1424542 · 2018 · External reference
Sarcopenia in liver transplantation: A review
10.1016/j.clnesp.2017.08.005 · 2017 · External reference
The association between sarcopenia and functional outcomes among older patients with hip fracture undergoing in-hospital rehabilitation
10.1007/s00198-017-3929-z · 2017 · External reference
Sarcopenia with limited mobility: An international consensus
10.1016/j.jamda.2011.04.014 · 2011 · External reference
Functional impact of 10 days of bed rest in healthy older adults
10.1093/gerona/63.10.1076 · 2008 · External reference
Criteria for clinically relevant weakness and low lean mass and their longitudinal association with incident mobility impairment and mortality: the Foundation for the National Institutes of Health (FNIH) sarcopenia project
10.1093/gerona/glu012 · 2014 · External reference
Associations of sarcopenia definitions, and their components, with the incidence of recurrent falling and fractures; the Longitudinal Aging Study Amsterdam
10.1093/gerona/glx245 · 2018 · External reference
An evidence-based comparison of operational criteria for the presence of sarcopenia
10.1093/gerona/glu013 · 2014 · External reference
Sarcopenia: Prevalence and associated factors based on different suggested definitions in community-dwelling older adults
10.1111/ggi.12723 · 2016 · External reference
Comparisons of sarcopenia defined by IWGS and EWGSOP criteria among older people: results from the I-Lan longitudinal aging study
10.1016/j.jamda.2013.03.019 · 2013 · External reference
Cut-off points for muscle mass - not grip strength or gait speed - determine variations in sarcopenia prevalence
10.1007/s12603-016-0844-5 · 2017 · External reference
Epidemiology of sarcopenia; in Clinical Guidelines for Sarcopenia, editor H. Arai
10.1111/ggi.13320 · 2018 · External reference
Implications of ICD-10 for Sarcopenia Clinical Practice and Clinical Trials: Report by the International Conference on Frailty and Sarcopenia Research Task Force
2018 · External reference
Unresolved reference
External reference
Pharmacological interventions in frailty and sarcopenia: Report by the International Conference on Frailty and Sarcopenia Research Task Force
2015 · External reference
Designing pharmaceutical trials for sarcopenia in frail older adults: EU/US Task Force recommendations
10.1007/s12603-013-0362-7 · 2013 · External reference
Working Group on Functional Outcome Measures for Clinical Trials: Indications, labeling, and outcomes assessment for drugs aimed at improving functional status in older persons: a conversation between aging researchers and FDA regulators
2009 · External reference
Unresolved reference
2016 · External reference
Unresolved reference
External reference
Developing and implementing performance outcome assessments: evidentiary, methodologic, and operational considerations
2018 · External reference
Validity and reliability of tools to measure muscle mass, strength, and physical performance in community-dwelling older people: a systematic review
10.1016/j.jamda.2012.10.009 · 2013 · External reference
Meaningful change and responsiveness in common physical performance measures in older adults
10.1111/j.1532-5415.2006.00701.x · 2006 · External reference
Physical performance measures in the clinical setting
10.1046/j.1532-5415.2003.51104.x · 2003 · External reference
Gait speed as a measure in geriatric assessment in clinical settings: A systematic review
10.1093/gerona/gls174 · 2012 · External reference
Grip strength cutpoints for the identification of clinically relevant weakness
10.1093/gerona/glu011 · 2014 · External reference
Cutpoints for low appendicular lean mass that identify older adults with clinically significant weakness
10.1093/gerona/glu023 · 2014 · External reference
Lower-extremity function in persons over the age of 70 years as a predictor of subsequent disability
10.1056/nejm199503023320902 · 1995 · External reference
Short Physical Performance Battery and allcause mortality: systematic review and meta-analysis
10.1186/s12916-016-0763-7 · 2016 · External reference
A short physical performance battery assessing lower extremity function: association with self-reported disability and prediction of mortality and nursing home admission
10.1093/geronj/49.2.m85 · 1994 · External reference
Performance-based or self-report measures of physical function: which should be used in clinical trials of hip fracture patients
10.1016/j.apmr.2008.04.016 · 2008 · External reference
Magnitude and patterns of decline in health and function in 1 year affect subsequent 5-year survival
10.1093/gerona/60.7.894 · 2005 · External reference
Lower extremity function and subsequent disability: consistency across studies, predictive models, and value of gait speed alone compared with the short physical performance battery
10.1093/gerona/55.4.m221 · 2000 · External reference
Prognostic significance of the short physical performance battery in older patients discharged from acute care hospitals
10.1089/rej.2011.1215 · 2012 · External reference
Are estimates of meaningful decline in mobility performance consistent among clinically important subgroups? (Health ABC study)
10.1093/gerona/glu033 · 2014 · External reference
Effect of a home-based exercise program on functional recovery following rehabilitation after hip fracture: a randomized clinical trial
10.1001/jama.2014.469 · 2014 · External reference
Comprehensive geriatric care for patients with hip fractures: a prospective, randomised, controlled trial
10.1016/s0140-6736(14)62409-0 · 2015 · External reference
Gait speed at usual pace as a predictor of adverse outcomes in community-dwelling older people an International Academy on Nutrition and Aging (IANA) Task Force
10.1007/s12603-009-0246-z · 2009 · External reference
Role of gait speed in the assessment of older patients
10.1001/jama.2010.1970 · 2011 · External reference
Gait speed and survival in older adults
10.1001/jama.2010.1923 · 2011 · External reference
Walking pace and the risk of cognitive decline and dementia in elderly populations: A meta-analysis of prospective cohort studies
10.1093/gerona/glw121 · 2017 · External reference
The nonlinear relationship between gait speed and falls: the Maintenance of Balance, Independent Living, Intellect, and Zest in the Elderly of Boston Study
10.1111/j.1532-5415.2011.03408.x · 2011 · External reference
The loss of skeletal muscle strength, mass, and quality in older adults: the health, aging and body composition study
10.1093/gerona/61.10.1059 · 2006 · External reference
Muscle weakness and physical disability in older Americans: Longitudinal findings from the U.S. Health and Retirement Study
10.1007/s12603-017-0951-y · 2018 · External reference
Digital health revolution: perfect storm or perfect opportunity for pharmaceutical R&D
10.1016/j.drudis.2016.01.010 · 2016 · External reference
Designing, implementing, and evaluating mobile health technologies for managing chronic conditions in older adults: A scoping review
10.2196/mhealth.5127 · 2016 · External reference
Recommendations for the conduct of clinical trials for drugs to treat or prevent sarcopenia
10.1007/s40520-015-0517-y · 2016 · External reference
Oral drugs related with muscle wasting and sarcopenia. A review
10.1159/000448247 · 2017 · External reference
Pharmacologic options for the treatment of sarcopenia
10.1007/s00223-015-0022-5 · 2016 · External reference
Development of selective androgen receptor modulators (SARMs)
10.1016/j.mce.2017.06.013 · 2018 · External reference
Effects of a novel selective androgen receptor modulator on dexamethasone-induced and hypogonadism-induced muscle atrophy
10.1210/en.2010-0150 · 2010 · External reference
A phase IIA randomized, placebocontrolled clinical trial to study the efficacy and safety of the selective androgen receptor modulator (SARM), MK-0773 in female participants with sarcopenia
10.1007/s12603-013-0335-x · 2013 · External reference
The selective androgen receptor modulator GTx-024 (enobosarm) improves lean body mass and physical function in healthy elderly men and postmenopausal women: results of a double-blind, placebocontrolled phase II trial
10.1007/s13539-011-0034-6 · 2011 · External reference
Regulation of skeletal muscle maßs in mice by a new TGF-ß superfamily member
10.1038/387083a0 · 1997 · External reference
Myostatin reduces Akt/TORC1/p70S6K signaling, inhibiting myoblast differentiation and myotube size
10.1152/ajpcell.00105.2009 · 2009 · External reference
TAK-1/p38/nNF?B signaling inhibits myoblast differentiation by increasing levels of Activin A
10.1186/2044-5040-2-3 · 2012 · External reference
GDF11 increases with age and inhibits skeletal muscle regeneration
10.1016/j.cmet.2015.05.010 · 2015 · External reference
Regulation of muscle growth by multiple ligands signaling through activin type II receptors
10.1073/pnas.0505996102 · 2005 · External reference
An antibody blocking activin type II receptors induces strong skeletal muscle hypertrophy and protects from atrophy
10.1128/mcb.01307-13 · 2014 · External reference
Blockade of activin type II receptors with a dual anti-ActRIIA/IIB antibody is critical to promote maximal skeletal muscle hypertrophy
10.1073/pnas.1707925114 · 2017 · External reference
Myostatin mutation associated with gross muscle hypertrophy in a child
10.1056/nejmoa040933 · 2004 · External reference
Myostatin antibody (LY2495655) in older weak fallers: a proof-of-concept, randomised, phase 2 trial
10.1016/s2213-8587(15)00298-3 · 2015 · External reference
Safety, tolerability, pharmacokinetics, and pharmacodynamics of domagrozumab (PF-06252616), an anti-myostatin monoclonal antibody in healthy subjects
10.1002/cpdd.386 · 2018 · External reference
Activin A more prominently regulates muscle mass in primates than does GDF8
10.1038/ncomms15153 · 2017 · External reference
Myostatin neutralization results in preservation of muscle mass and strength in preclinical models of tumor-induced muscle wasting
10.1158/1535-7163.mct-14-0681 · 2015 · External reference
10.1186/s13395-017-0141-y
10.1186/s13395-017-0141-y · 2017 · External reference
Effect of bimagrumab on thigh muscle volume and composition in men with casting-induced atrophy
10.1002/jcsm.12205 · 2017 · External reference
Treatment of sarcopenia with bimagrumab: Results from a phase II, randomized, controlled, proof-of-concept study
10.1111/jgs.14927 · 2017 · External reference
Administration of a soluble activin type IIB receptor promotes skeletal muscle growth independent of fiber type
10.1152/japplphysiol.00866.2009 · 2010 · External reference
A single ascending-dose study of muscle regulator ACE-031 in healthy volunteers
10.1002/mus.23539 · 2013 · External reference
Myostatin inhibitor ACE-031 treatment of ambulatory boys with Duchenne muscular dystrophy: Results of a randomized, placebo-controlled clinical trial
10.1002/mus.25268 · 2017 · External reference
ACE-083 increases muscle hypertrophy and strength in C57BL/6 mice
2015 · External reference
ACE-083, a locally-acting TGF-ß; superfamily ligand trap, increases muscle mass and strength in a mouse model of Duchenne muscular dystrophy
10.1016/j.nmd.2016.06.160 · 2016 · External reference
Locally acting ACE-083 increases muscle volume in healthy volunteers
10.1002/mus.26113 · 2018 · External reference
A phase I/IItrial of MYO-029 in adult subjects with muscular dystrophy
10.1002/ana.21338 · 2008 · External reference
Pharmacological inhibition of myostatin and changes in lean body mass and lower extremity muscle size in patients receiving androgen deprivation therapy for prostate cancer
10.1210/jc.2014-1271 · 2014 · External reference
A phase 2 randomized study investigating the efficacy and safety of myostatin antibody LY2495655 versus placebo in patients undergoing elective total hip arthroplasty
2016 · External reference
Unresolved reference
External reference
Blockade of GDF8 and activin A lead to increases in thigh muscle volume in healthy postmenopausal women: A single ascending dose study. International Conference on Frailty and Sarcopenia Research
2018 · External reference
Bimagrumab improves body composition and insulin sensitivity in insulin-resistant individuals
10.1111/dom.13042 · 2018 · External reference
Effects of bimagrumab, an activin receptor type II inhibitor, on pituitary neurohormonal axes
10.1111/cen.13601 · 2018 · External reference
CK-2127107 amplifies skeletal muscle response to nerve activation in humans
10.1002/mus.26017 · 2018 · External reference
